TG THERAPEUTICS, INC. financials

TGTX CIK 0001001316

Source: EDGAR filings · Built 2026-06-02T04:10:26Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -24.99M -40.56M -31.41M -176.18M -296.04M -214.86M
EBITDA 123.38M 42.00M 20.84M -218.01M -344.49M -273.22M
Working Capital 477.00M 475.68M 264.22M 115.07M 265.58M 524.19M
Net Debt 174.56M 73.83M 18.15M -19.24M -219.84M -511.46M
Gross Margin 83.66% 88.30% 93.95% 90.48% 88.19%
Operating Margin 20.01% 12.74% 8.83% -7838.99% -5154.28% -179996.05%
Net Margin 72.56% 7.11% 5.42% -8036.34% -5204.08% -183803.29%
Return on Equity (ROE) 69.01% 10.52% 7.90% -382.02% -146.78% -53.79%
Return on Assets (ROA) 42.06% 4.05% 3.84% -115.62% -91.69% -44.66%
Current Ratio 4.10× 6.25× 5.92× 3.16× 5.06× 6.99×
Debt-to-Equity 0.39× 1.14× 0.69× 1.42× 0.33× 0.08×
Effective Tax Rate -316.41% 8.64% 2.99% 0.00% 0.00% 0.00%
Cash Conversion Ratio -0.06× -1.73× -2.48× 0.79× 0.85× 0.77×
Accruals Ratio 0.44× 0.11× 0.13× -0.25× -0.14× -0.10×
SBC % of Revenue 10.49% 12.93% 16.23% 1603.66% 916.04% 52821.71%
CapEx Coverage -115.76× -900.38× -12583.57× -737.24× -600.86×
Free Cash Flow Per Share $-0.15 $-0.25 $-0.21 $-1.30 $-2.24 $-1.86

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 10.76× 200.67× 189.78×
EV / EBITDA 38.94× 113.45× 124.95×
P/S 7.51× 14.26× 11.07× 621.81× 406.90×
P/B 7.14× 21.09× 16.11× 29.56× 11.48× 14.08×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 616.29M 329.00M 233.66M 2.79M 6.69M
Revenues 2.79M 6.69M 152.00K
Cost of Goods and Services Sold 100.71M 38.49M 14.13M 265.00K 790.00K
Research and Development Expense 160.22M 94.29M 76.19M 125.35M 222.58M 165.90M
Selling, General and Administrative Expense 232.03M 154.30M 122.71M 95.48M 128.09M 107.85M
Operating Expenses 195.62M 351.46M 273.75M
Operating Income (Loss) 123.32M 41.93M 20.63M -218.32M -344.77M -273.59M
Income Tax Expense (Benefit) -339.79M 2.21M 390.00K 0 0 0
Net Income (Loss) Attributable to Parent 447.18M 23.38M 12.67M -223.81M -348.10M
Earnings Per Share, Basic $3.10 $0.16 $0.09 $-1.65 $-2.63 $-2.42
Weighted Average Number of Shares Outstanding, Basic 144.32M 145.32M 141.96M 135.41M 132.22M 115.33M
Earnings Per Share, Diluted $2.77 $0.15 $0.09 $-1.65 $-2.63 $-2.42
Weighted Average Number of Shares Outstanding, Diluted 161.41M 160.34M 148.51M 135.41M 132.22M 115.33M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 79.15M 179.89M 92.93M 102.30M 298.89M 553.44M
Assets, Current 630.76M 566.36M 317.94M 168.27M 330.96M 611.74M
Assets 1.06B 577.69M 329.59M 193.57M 379.63M 625.64M
Long-term Debt 100.40M 71.14M 67.76M 29.89M
Liabilities, Current 153.76M 90.68M 53.72M 53.20M 65.38M 87.55M
Long-term Debt, Excluding Current Maturities 245.65M 244.43M 100.12M 71.14M 66.79M 7.72M
Liabilities 415.23M 355.33M 169.09M 134.99M 142.48M 106.29M
Stockholders' Equity Attributable to Parent 648.02M 222.36M 160.50M 58.59M 237.15M 519.35M
Common Stock, Shares, Outstanding 155.31M 155.84M 151.42M 146.39M 143.25M 140.58M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -24.77M -40.52M -31.41M -176.17M -295.63M -214.51M
Payments to Acquire Property, Plant, and Equipment 214.00K 45.00K 0 14.00K 401.00K 357.00K
Net Cash Provided by (Used in) Investing Activities 13.80M -1.04M -50.65M -20.01M -332.00K -24.51M
Net Cash Provided by (Used in) Financing Activities -89.73M 128.53M 72.70M -391.00K 41.42M 679.83M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (TGTX CIK 0001001316), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

DRVN

Driven Brands Holdings Inc.

NEOG

Neogen Corporation

VRE

VERIS RESIDENTIAL, INC.